Using Blood-Based Epigenetic Signatures to Personalize First-Line Biologic Therapy in Crohn’s Disease
- Investigating a scalable, blood-derived DNA methylation panel designed to guide first-line biologic selection at diagnosis, aiming to move beyond today’s trial-and-error paradigm and reduce early complications linked to ineffective therapy
- Leveraging a validated epigenetic algorithm undergoing testing in the OMICRON clinical trial to improve therapeutic success rates
- Establishing a blueprint for cross-disease precision medicine, with methylation markers and machine-learning pipelines engineered for translation